Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.55 |
| ▸ | PPARG | P37231 | 13/20 | 0.55 |
| ▸ | PPARD | Q03181 | 5/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 4/20 | 0.54 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.53 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720354 | 1.00 | PPARA (0.55) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL1368490 | 1.00 | PPARA (0.55) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL12581017 | 0.86 | SRR (0.42) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL14392119 | 0.85 | PPARG (0.81) | PPARAPPARGPPARDSRRPSAT1 | |
| Methylamine SCHEMBL5607639 | 0.84 | SLC7A5 (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL16451001 | 0.84 | ESR1 (0.45) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL3466702 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL4451311 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL4941128 | 0.84 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL9628212 | 0.83 | SRR (0.70) | PPARAPPARGPPARDSRRPSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | claimed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | claimed |
| EP-3628317-A1 | METHODS OF TREATING FIBROSIS | Nogra Pharma Limited (IE) | 2020-04-01 | — | — | EP | claimed |
| EP-2811993-B1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LTD (IE) | 2019-10-09 | — | — | EP | claimed |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2018-07-10 | — | — | US | claimed |
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2017-11-02 | — | — | US | claimed |
| US-9682050-B2 | Methods of treating lactose intolerance | NOGRA PHARMA LIMITED (IE) | 2017-06-20 | — | — | US | claimed |
| US-9561202-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2017-02-07 | — | — | US | claimed |
| US-9345680-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2016-05-24 | — | — | US | claimed |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | claimed |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | GIULIANI INTERNATIONAL LIMITED (IE) | 2015-09-24 | — | — | US | claimed |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2015-03-26 | — | — | US | claimed |
| EP-2844242-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | Nogra Pharma Limited (IE) | 2015-03-11 | — | — | EP | claimed |
| WO-2013156413-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | NOGRA PHARMA LIMITED (IE) | 2013-10-24 | — | — | WO | claimed |
| US-20260115159-A1 | ALKYLAMIDO COMPOUNDS AND USES THEREOF | NOGRA PHARMA LTD (IE) | 2026-04-30 | — | — | US | disclosed |
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | disclosed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | disclosed |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | NOGRA PHARMA LIMITED (IE) | 2011-11-24 | — | — | US | disclosed |
| WO-2010091892-A2 | ALKYLAMIDO COMPOUNDS AND USES THEREOF | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-08-19 | — | — | WO | disclosed |
| WO-2010091894-A2 | METHODS OF TREATING HAIR RELATED CONDITIONS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312239-A1 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | EGFR, ERBB3, FGFR3 | PPARA 9/4885PPARG 4/4885PPARD 12/4885 |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | PPARA 9/4885PPARG 4/4885PPARD 12/4885 |
| US-20150265562-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | PPARA 9/4885PPARG 4/4885PPARD 12/4885 |
| US-20150265563-A1 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field | EGFR, ERBB3, FGFR3 | PPARA 9/4885PPARG 4/4885PPARD 12/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
| US-20150087678-A1 | METHODS OF TREATING LACTOSE INTOLERANCE | LCT, LPL, PPARG | PPARA 4/4885PPARG 3/4885PPARD 6/4885 |
| US-20260115159-A1 | ALKYLAMIDO COMPOUNDS AND USES THEREOF | EGFR, PPARD, PPARG | PPARA 4/4885PPARG 3/4885PPARD 2/4885 |
| US-20110288177-A1 | Methods for Preventing or Reducing Colon Carcinogenesis | APC, GSTK1, GSTA1 | PPARA 186/4885PPARG 275/4885PPARD 706/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | PPARA 648/4885PPARG 669/4885PPARD 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.